Resumen de acción BHC Bausch Health Companies Inc. opera como empresa diversificada de especialidades farmacéuticas y dispositivos médicos en Estados Unidos y a escala internacional. Saber más
Recompensas Análisis de riesgos Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de Bausch Health Companies Inc. Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del Bausch Health Companies Precios históricos de las acciones Precio actual de la acción US$10.85 Máximo en las últimas 52 semanas US$15.43 Mínimo de 52 semanas US$5.45 Beta 0.69 Cambio en 1 mes -4.74% Variación en 3 meses -2.69% Cambio de 1 año 2.07% Variación en 3 años -68.95% Variación en 5 años -71.60% Variación desde la OPV 1,695.85%
Noticias y actualizaciones recientes
Bausch Health Companies Inc. Appoints Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D Dec 02
Bausch Health Companies Inc. Receives Positive Reimbursement Recommendations for Cabtreo in Canada Nov 19
Forecast breakeven date pushed back to 2025 Nov 03
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 01
Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Results of an Analysis of Xifaxan (rifaximin) Monotherapy Will Be Presented During A Presidential Plenary Session of the American College of Gastroenterology 2024 Annual Scientific Meeting Taking Place October 25-30 in Philadelphia, PA Oct 28
Bausch Health Companies Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 10 Ver más actualizaciones
Bausch Health Companies Inc. Appoints Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D Dec 02
Bausch Health Companies Inc. Receives Positive Reimbursement Recommendations for Cabtreo in Canada Nov 19
Forecast breakeven date pushed back to 2025 Nov 03
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 01
Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Results of an Analysis of Xifaxan (rifaximin) Monotherapy Will Be Presented During A Presidential Plenary Session of the American College of Gastroenterology 2024 Annual Scientific Meeting Taking Place October 25-30 in Philadelphia, PA Oct 28
Bausch Health Companies Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 10
Health Canada Approves the Bausch Health's (Pr)CABTREO Topical Gel Sep 11
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 02
Bausch Health Companies Inc. Raises Earnings Guidance for the Full Year 2024 Aug 01 Bausch Health Companies Inc. Announces Appointment of Aimee Lenar as Executive Vice President, US Pharma
Bausch Health Companies Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 12
Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024 May 18
Bausch Health Companies Inc. Approves Directorate Appointments May 16
First quarter 2024 earnings: EPS misses analyst expectations May 03
Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan Apr 13
Bausch Health Companies Inc. to Report Q1, 2024 Results on May 02, 2024 Apr 12
Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults Apr 03
Insufficient new directors Apr 01
Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma Mar 06
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Feb 23
Bausch Health Companies Inc., Annual General Meeting, May 14, 2024 Feb 21 Bausch Health Companies Inc. to Report Q4, 2023 Results on Feb 22, 2024
Bausch Health Companies Inc. Announces the U.S. Launch of CABTREO Topical Gel Jan 31
Bausch Health Companies Inc. and Salix Pharmaceuticals Ltd. Provides Update on Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute Jan 09
Bausch Health Companies Inc. Announces Positive Topline Results from Global Phase 2 Study Evaluating Amiselimod (An S1p Antagonist) to Treat Ulcerative Colitis Dec 22
Bausch Health, Canada Announces DUOBRII Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec's Public Drug Plan Dec 19
Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 02
FDA Approves Bausch Health Companies Inc. and Its Dermatology Business, Ortho Dermatologics's Cabtreo Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older Oct 21
Bausch Health Companies Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 13 Bausch Health Companies Inc. Announces Executive Changes
Bausch Health Companies Inc. Announces New Treatment PrUCERIS (Budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults Sep 14
Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc Sep 08
Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc Sep 06
Bausch Health Companies Inc. Raises Earnings Guidance for the Fiscal Year 2023 Aug 04
Second quarter 2023 earnings released: EPS: US$0.072 (vs US$0.40 loss in 2Q 2022) Aug 04
Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Purchasers of Bausch Health Companies Inc Jul 27
Bausch Health Companies Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 14
New major risk - Financial position Jul 01
Forecast to breakeven in 2025 May 10
First quarter 2023 earnings: EPS misses analyst expectations May 06
Bausch Health Companies Inc. Provides Consolidated Earnings Guidance for the Full Year 2023 May 05
Forecast breakeven date pushed back to 2025 Apr 18
Full year 2022 earnings: EPS misses analyst expectations Feb 24
Investor sentiment improves as stock rises 23% Feb 16
Bausch Health Companies Inc. to Report Q4, 2022 Results on Feb 23, 2023 Feb 02
Investor sentiment improved over the past week Jan 06
Bausch Health Companies Inc. Announces Availability of ARAZLOTM Dec 23
Investor sentiment deteriorated over the past week Dec 22
Investor sentiment improved over the past week Dec 02
Third quarter 2022 earnings: EPS exceeds analyst expectations Nov 04
Bausch Health Companies Inc. Revises Consolidated Earnings Guidance for the Full Year 2022 Nov 04
Bausch Health Companies Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 14
Bausch Health Companies Inc. and Glenmark Specialty S.A. Announce the Approval of RYALTRIS® in Canada Sep 23
Insider recently sold CA$932k worth of stock Sep 21 Bausch Health Companies Inc.(TSX:BHC) dropped from FTSE All-World Index (USD)
Bausch Health Companies Inc. Responds to Norwich Pharmaceuticals Tentative FDA Approval for 200 mg Rifaximin Sep 10
Investor sentiment improved over the past week Sep 07
Investor sentiment improved over the past week Aug 16 Bausch Health Companies Inc. to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Aug 10 Bausch Health Companies Inc. Announces Unaudited Impairment Results for the Quarter Ended June 30, 2022
Insufficient new directors Jul 31
Bausch Health Companies Inc. to Report Q2, 2022 Results on Aug 09, 2022 Jul 28
Insufficient new directors Jul 01
Bausch Health Companies Inc. Announces Updates to Its Board of Directors Jun 24
Bausch Health Companies Inc. Appoints John S. Barresi as the Company’s Senior Vice President, Controller and Chief Accounting Officer Jun 01
Bausch Health Companies Inc. Provides Revenue Guidance for the Year Full Year 2022 May 12
Bausch Health Companies Inc. Announces Management Changes May 08
Bausch Health Companies Inc. to Report Q1, 2022 Results on May 10, 2022 May 02
Bausch Health Companies Inc., Annual General Meeting, Jun 14, 2022 Apr 02
Full year 2021 earnings: EPS misses analyst expectations Feb 26 Bausch Health Companies Inc. Provides Earnings Guidance for the Year 2022
Bausch Health, Canada Announces Availability through Pharmacies Across Canada of its New Prescription Treatment TRULANCE Feb 09
Bausch Health Companies Inc. to Report Q4, 2021 Results on Feb 23, 2022 Feb 04
Bausch Health Companies Inc. has filed an IPO. Jan 15
Bausch Health Companies Inc. Announces New Post-Hoc Analysis of Pooled Results on the Safety and Efficacy of A Single Dose of Relistor Injection Dec 23
Insider recently bought CA$1.9m worth of stock Dec 03
Third quarter 2021 earnings released: EPS US$0.52 (vs US$0.20 in 3Q 2020) Nov 03
Independent Director recently bought CA$314k worth of stock Aug 07
Bausch Health Companies Inc. Revises Earnings Guidance for the Year 2021 Aug 05
Second quarter 2021 earnings released: US$1.66 loss per share (vs US$0.92 loss in 2Q 2020) Aug 04
Abu Dhabi Developmental Holding Company PJSC completed the acquisition of Amoun Pharmaceutical Company S.A.E. from Bausch Health Companies Inc. (NYSE:BHC) and others. Aug 04
Bausch + Lomb Expands Parameters for Bausch + Lomb Ultra® Multifocal for Astigmatism Contact Lenses Jun 24
Independent Director David Hale has left the company Jun 22
CFO & Executive VP recently sold CA$655k worth of stock Jun 16
Bausch Health and Clearside Biomedical Announce U.S. FDA Filing Acceptance for XIPERE (Triamcinolone Acetonide Suprachoroidal Injectable Suspension) Jun 03
Independent Director recently sold CA$425k worth of stock May 30
Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Four Scientific Poster Presentations Featuring Data for XIFAXAN May 18
Bausch Health Companies Inc. Announces New Data from the National Eye Reaffirms the Clinical Outcomes of the AREDS2 Study May 13
First quarter 2021 earnings released: US$1.71 loss per share (vs US$0.43 loss in 1Q 2020) May 07
Bausch Health Companies Inc. Reiterates Revenue Guidance for the Full Year of 2021 May 05
Bausch Health Reportedly Explores Eye-Care Unit Sale Apr 29 Rentabilidad de los accionistas BHC CA Pharmaceuticals Mercado CA 7D 1.3% 1.2% 1.0% 1Y 2.1% -30.7% 15.9%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: BHC superó a la industria Canadian Pharmaceuticals, que obtuvo un rendimiento del -30.7% el año pasado.
Rentabilidad vs. Mercado: BHC obtuvo unos resultados inferiores a los del mercado Canadian, que fueron del 15.9% el año pasado.
Volatilidad de los precios Is BHC's price volatile compared to industry and market? BHC volatility BHC Average Weekly Movement 7.0% Pharmaceuticals Industry Average Movement 12.1% Market Average Movement 8.2% 10% most volatile stocks in CA Market 17.3% 10% least volatile stocks in CA Market 3.0%
Precio estable de las acciones: BHC no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de BHC (7%) se ha mantenido estable durante el año pasado.
Acerca de la empresa Bausch Health Companies Inc. opera como una empresa diversificada de especialidades farmacéuticas y dispositivos médicos en Estados Unidos y a escala internacional. Desarrolla, fabrica y comercializa una gama de productos principalmente en gastroenterología, hepatología, neurología, dermatología, productos farmacéuticos internacionales, productos de venta libre (OTC), dispositivos médicos estéticos y salud ocular. La empresa opera a través de cinco segmentos: Salix, Internacional, Solta Medical, Diversified y Bausch + Lomb.
Mostrar más Resumen de fundamentos de Bausch Health Companies Inc. ¿Cómo se comparan los beneficios e ingresos de Bausch Health Companies con su capitalización de mercado? Estadísticas fundamentales de BHC Capitalización bursátil CA$4.03b Beneficios(TTM ) -CA$256.55m Ingresos (TTM ) CA$13.65b
0.3x Ratio precio-ventas (PS)
-15.7x Ratio precio-beneficio (PE) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de BHC Ingresos US$9.47b Coste de los ingresos US$2.76b Beneficio bruto US$6.71b Otros gastos US$6.89b Beneficios -US$178.00m
Últimos beneficios comunicados
Sep 30, 2024
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) -0.48 Margen bruto 70.87% Margen de beneficio neto -1.88% Ratio deuda/patrimonio -8,887.2%
¿Cómo se ha desempeñado BHC a largo plazo?
Ver rendimiento histórico y comparativa
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2024/12/27 05:28 Precio de las acciones al final del día 2024/12/24 00:00 Beneficios 2024/09/30 Ingresos anuales 2023/12/31
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .
Fuentes analistas Bausch Health Companies Inc. está cubierta por 46 analistas. 7 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución Raghuram Selvaraju Aegis Capital Corporation Douglas Tsao Barclays Ardalan Arfaei BMO Capital Markets Equity Research
Mostrar 43 más analistas 
